ENDRA Life Sciences Inc. 8-K Summary
Business Context and Reporting Period
ENDRA Life Sciences Inc., an emerging growth company incorporated in Delaware, filed this Current Report on Form 8-K on August 17, 2020. The filing serves to announce the company's financial results for the quarter and year ended June 30, 2020, via a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the attached press release (Exhibit 99.1), which is not included in the source text.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. It only confirms the issuance of results for the period ended June 30, 2020.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information in Item 2.02 and Exhibit 99.1 is furnished and not deemed "filed" under Section 18 of the Securities Exchange Act of 1934. Consequently, the text does not contain specific management commentary, forward-looking guidance, risk factors, or details on contingencies and unusual items.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 17, 2020) for actual revenue, net loss, and cash position figures.
- Verify the company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.
- Confirm the trading symbols (NDRA for Common Stock, NDRAW for Warrants) on The Nasdaq Stock Market LLC.
- Check subsequent filings for any updates to the financial results announced in this 8-K.